Peroxisome proliferator-activated receptor-c (PPARc) is a nuclear receptor for eicosanoids that promotes differentiation of human epithelial and mesenchymal cells in vitro and in vivo. PPARc was proposed as a target for drug-induced differentiation therapy of cancer. Caveolin-1 is a constituent of plasma membrane caveolae in epithelial cells that is often downregulated upon oncogenic transformation. Caveolin-1 has growth-inhibitory activities and its disruption is sufficient to induce transformation in fibroblasts. Herein we have tested the hypothesis that caveolins are transcriptional target genes for PPARc. In human HT-29 colon carcinoma cells, thiazolidinedione PPARc ligands increased the levels of caveolin-1 and caveolin-2 proteins two to fivefold in a concentrationdependent manner within 24 h. In human MCF-7 breast adenocarcinoma cells, nonthiazolidinedione PPARc ligands elevated caveolin-2 protein three to fourfold, while the thiazoli-dinediones were less effective. Caveolin-1 mRNA levels were found to be upregulated by PPARc ligands already after 3 h in both the cell lines. Ectopic expression of a dominant-negative PPARc construct attenuated ligand-induced upregulation of caveolins in both HT-29 and HEK-293T cells, indicating that ligand action is mediated by PPARc. Ligand-treated MCF-7 cells exhibited a differentiated phenotype, as evinced by analysis of cell-specific differentiation markers: protein levels of maspin were elevated and perinuclear lipid droplets accumulated. In contrast, in HT-29 cells, caveolin expression was not correlated with differentiation. Interestingly, PPARc partially cofractionated in lipid rafts and could be coimmunoprecipitated from cell lysates with caveolin-1, indicating that PPARc and caveolin-1 may coexist in a complex. Our data indicate that PPARc participates in the regulation of caveolin gene expression in human carcinoma cells and suggest that caveolin-1 may mediate some of the phenotypic changes induced by this nuclear receptor in cancer cells. These findings may have potentially important functional implications in the context of cancer differentiation therapy and multidrug resistance.
Introduction
The caveolin gene family comprises three 22-24-kDa integral membrane proteins (caveolin-1, -2 and -3) that are constituents of sphingolipid-and cholesterol-rich invaginations of the plasma membrane termed caveolae (Schlegel and Lisanti, 2001) . Caveolins act as scaffold proteins that sequester and organize lipids (e.g. cholesterol, sphingolipids) and proteins (e.g. receptor and nonreceptor tyrosine kinases, G proteins) in multimolecular signaling complexes Brown and London, 2000) . Additionally, caveolae have been implicated in clathrin-independent endocytosis (Anderson, 1998) and in cholesterol efflux from cells (Fielding and Fielding, 2001) . Caveolin gene expression is highly regulated, but the mechanisms involved in their transcriptional regulation are poorly understood.
Caveolin-1 expression is reversibly downregulated in mitotic cells, but is upregulated after establishment of cell-cell contacts in quiescent, confluent fibroblasts (Galbiati et al., 1998a) or upon cell senescence (Park et al., 2000) . Accordingly, caveolin-1 and -2 are most abundantly expressed in terminally differentiated cells of the mesenchymal (adipose/muscle), endothelial, epithelial, neuronal and macrophage lineages (Scherer et al., 1994 (Scherer et al., , 1997 Song et al., 1996; Galbiati et al., 1998b; Campbell et al., 1999; Matveev et al., 1999; Liu et al., 2002) . In contrast, caveolin-1 mRNA and protein levels are strongly reduced in oncogenically transformed cells (Koleske et al., 1995; Engelman et al., 1998b) and in many (but not all) human cancer cells (Lee et al., 1998; Hurlstone et al., 1999; Racine et al., 1999; Bagnoli et al., 2000; Bender et al., 2000; Wiechen et al., 2001 ). This downregulation is caused by deletions within the CAV1/ CAV2 locus (Engelman et al., 1998c; Fra et al., 1999) or by silencing of the CAV1 promoter (Engelman et al., 1999a) . Mitogenic signaling pathways negatively regulate transcription of the caveolin-1 and -2 genes (Engelman et al., 1999b) . The cAMP/PKA pathway exerts a similar effect (Yamamoto et al., 1999) . Several transcription factors including a complex of E2F/DP-1, SP-1 and p53 (Bist et al., 2000; Razani et al., 2000) , c-Myc (Park et al., 2001 ) and sterol-regulatory element binding protein (Bist et al., 1997) mediate downregulation of the caveolin-1 promoter. However, the detailed organization of the CAV1 and CAV2 promoters has not been fully elucidated (Engelman et al., 1999a; Fra et al., 1999) . There is little evidence for transcription factors that positively regulate caveolin-1 or -2 expression. The basic helix-loop-helix transcription factors, myogenin and Id2, mediate tissue-specific induction of caveolin-3 gene in muscle cells (Biederer et al., 2000) . Recent reports indicate the involvement of members of the nuclear receptor superfamily. Both androgens (Li et al., 2001a) and estrogens (Razandi et al., 2002) induce transcription of caveolin-1 via their cognate receptors in a sex-specific manner.
Peroxisome proliferator-activated receptor-g (PPARg) is a nuclear receptor targeted by endogenous prostaglandins and leukotrienes (Fajas et al., 2001; Rosen and Spiegelman, 2001) . Additionally, a variety of insulinsensitizing drugs like thiazolidinediones (glitazones) (Murphy and Holder, 2000) and phenylacetic acids (Samid et al., 2000) are selective PPARg ligands. PPARg forms heterodimers with the retinoid X receptor (RXR), which binds to PPAR-responsive elements (PPRE) and modulate transcription by crosstalk with other nuclear factors. PPARg regulates transcription of genes involved in the immune response, lipid/carbohydrate metabolism and differentiation of epithelial and mesenchymal cells in vitro and in vivo (Fajas et al., 2001; Rosen and Spiegelman, 2001) . Importantly, PPARg ligands induce differentiation in human breast cancer (Tontonoz et al., 1997; Mueller et al., 1998) and colon cancer (Kitamura et al., 1999) cell lines and prevent in vivo tumor formation in mouse xenograft tumor models (Elstner et al., 1998; Kubota et al., 1998) . PPARg ligands are undergoing phase II clinical trials for use in tumor differentiation therapy of human liposarcoma (Demetri et al., 1999) and carcinomas of the prostate (Mueller et al., 2000) .
PPARg was shown to be a differentiation-promoting transcription factor in adipogenesis (Fajas et al., 2001; Rosen and Spiegelman, 2001 ). Both caveolin-1 and -2 levels increase dramatically during differentiation of preadipocytes to adipocytes (Scherer et al., 1994 (Scherer et al., , 1997 . Human MCF-7 breast adenocarcinoma and human HT-29 colon adenocarcinoma cells, wherein caveolin expression is normally downregulated, express a functional PPARg with transcriptional activity (Kilgore et al., 1997; Lefebvre et al., 1999) and undergo differentiation in vitro upon cultivation with PPARg ligands (Mueller et al., 1998; Kitamura et al., 1999; Pignatelli et al., 2001) . The ability of PPARg to promote lineage-specific differentiation and the fact that caveolins are characteristic markers for terminally differentiated cells, raised the hypothesis that PPARg transcriptionally regulates caveolin expression. Herein we have utilized MCF-7 and HT-29 cells to test this hypothesis by examining if PPARg ligands can restore caveolin-1 and -2 protein expression in these cancer cells. Our results indicate that PPARg is a transcriptional regulator of caveolin gene expression in human adenocarcinoma cells and may thus have potentially important implications in the context of cancer differentiation therapy and multidrug resistance (MDR).
Results

Induction of caveolin-1 and -2 protein expression by PPARg ligands
We used selective ligands for PPARg in order to evaluate their effects on the expression of caveolin-1 and -2 in the human HT-29 colon and MCF-7 breast adenocarcinoma cell lines. Three classes of bona fide PPARg ligands were applied, including 15-desoxy-D 12,14 -prostaglandin J 2 (15dPGJ 2 ) as a physiological ligand, the glitazones (ciglitizone, troglitazone, rosiglitazone) and phenylacetate (PhAc). We first examined if PPARg ligands induce caveolin expression at confluency, a point that marks the onset of in vitro differentiation in HT-29 and MCF-7 cells. Cells were grown to monolayers and then treated with the ligands or vehicle (DMSO) for 3 additional days. Cell lysates were then tested for caveolin and actin expression by Western blotting. A quantitative analysis of the data obtained from HT-29 cells shows that caveolin-1 expression was upregulated between 3.070.4 and 5.270.6-fold in response to the glitazone ligands (at 10 mm) compared to vehicle-treated cells (Table 1) . Caveolin-2 expression in HT-29 cells was also increased by 2.670.4 to 3.170.2-fold by the glitazone drugs (Table 1) . Interestingly, 15dPGJ 2 and PhAc did not significantly increase caveolin-1 and -2 levels in HT-29 cells. In contrast, in MCF-7 cells, the expression of caveolin-2 was maximally elevated by 3.270.5 to 4.270.8-fold (Table 1) in response to 15dPGJ 2 and PhAc, while the glitazones were less effective. Caveolin-1 protein levels in MCF-7 cells remained below the detection limit under these assay conditions (but see below). From concentration-response experiments in HT-29 cells, we estimated an Figure 1a ). In MCF-7 cells, caveolin-2 levels were enhanced by PhAc in a concentration-dependent manner with an EC 50 of B1 mm ( Figure 1b ) and in response to 15dPGJ 2 with an EC 50 of B1 mm (Figure 1c ). These data indicate that various PPARg ligands are capable of inducing caveolin protein expression in human carcinoma cells, in which these genes are normally downregulated. However, different PPARg ligands differentially regulate caveolin-1 and -2 expression in a cell type-dependent manner.
In order to determine if caveolin induction by PPARg ligands is dependent on cell density, we performed timecourse experiments in which cells were seeded at low density (o30% confluency) and ligands were added to subconfluent cells. After reaching confluency, the cells were maintained for up to 5 days at postconfluency. In HT-29 cells, induction of caveolin-1 and -2 by rosiglitazone (10 mm) occurred in subconfluent cells within 24 h and caveolins were maintained elevated at confluency relative to vehicle controls over 2 additional days ( Figure 2a ) and up to 5 days (not shown). In contrast, Figure 1 Concentration dependence of changes in caveolin-1 and -2 expression induced by the three classes of PPARg ligands in (a) HT-29 and (b,c) MCF-7 cells. Cells were grown to confluency and incubated in the presence of increasing concentrations of the indicated ligand or vehicle for 3 days. Total cell lysates were then prepared and analysed for caveolin and actin expression by SDS-PAGE followed by Western blot as described under Materials and methods. The summary of densitometric analyses from at least three independent experiments is displayed beside a representative Western blot for the given ligand. Values represent the mean-fold increase7s.d. of caveolin-1 or -2 expression in ligand-treated vs control cells, calculated from the OD of the bands and normalized to the total amount of protein. Open circles, caveolin-1; solid circles, caveolin-2 Induction of caveolin by PPARc E Burgermeister et al the levels of caveolin-1 and -2 in vehicle-treated cells declined over the same time period, a phenomenon that has not yet been described. In MCF-7 cells, caveolin-2 levels were already maximally upregulated by PhAc after 24 h and declined somewhat after 2 days ( Figure 2b ). Upon confluency (day 3), caveolin-2 levels rose also in control cells, an observation that may be attributable to spontaneous differentiation at postconfluency. These data indicate that the induction of caveolin expression by PPARg ligands is an early event that occurs independently of cell density.
PPARg ligands upregulate caveolin-1 mRNA levels
To verify that PPARg ligands induce caveolin expression via an acute ligand-dependent activation of PPARg's transcriptional activity, we examined their effect on caveolin-1 mRNA steady-state levels ( Figure 3 ). HT-29 and MCF-7 cells were again seeded at low density (o50% confluency), 10 mm ciglitizone or 5 mm PhAc, respectively, was added for 2 days and cells were harvested before reaching confluency. Total RNA was extracted and the amounts of caveolin-1 mRNA were determined by RT-PCR. Total RNA from HT-29 MDR cells was used as a positive control since these cells express high levels of caveolin-1 protein and mRNA (Lavie et al., 1998; Fiucci et al., 2000) . Caveolin-1 mRNA steady-state levels were maximally upregulated 3.170.9-fold by ciglitizone in HT-29 and 3.571.7-fold by PhAc in MCF-7 compared to vehicle-treated cells (Figure 3a) . In contrast, the mRNA coding for the ribosomal protein S16 was unchanged, as was the amount of total RNA, visualized by comparison of the 28S ribosomal RNA bands (Figure 3b, c) . We then examined the short time course of caveolin-1 mRNA induction upon 3-24 h of ligand addition in subconfluent cells (Figure 3d ,e). In both cell lines, PPARg ligands induced an acute upregulation of caveolin-1 mRNA levels, which peaked between 3 and 6 h, decreased after 9 h and recovered after 24 h. These results clearly indicate that PPARg ligands upregulate caveolin-1 mRNA levels in an acute ligand-dependent manner.
Dominant-negative PPARg attenuates upregulation of caveolin expression
In order to form heterodimers, transactivate promoters and recruit coactivators, PPARg requires the activation function-2 (AF-2) domain comprising the 16 C-terminal Induction of caveolin by PPARc E Burgermeister et al amino acids (Nolte et al., 1998) . Deletion mutants of PPARg that lack the C-terminal 5-16 amino-acid residues of the AF-2 domain thus act in a dominantnegative manner and were utilized to verify that the ligands used herein upregulated caveolin expression via interaction with PPARg. The wild-type human PPARg1 or the truncated dominant-negative construct DNPPARgD459 was transiently transfected into subconfluent HT-29 cells ( Figure 4 ) and HEK-293 T cells ( Figure 5 ). In order to measure the transactivating potential of endogenous and ectopically transfected PPARg, subconfluent cells were cotransfected with the PPRE-luciferase reporter plasmid. After transfection, cells were incubated for 48 h with 10 mm rosiglitazone. Luciferase activity and the amount of caveolin were determined in total cell lysates. In control, mocktransfected HT-29 cells, rosiglitazone elevated luciferase activity 1.570.2-fold against an already high background in vehicle-treated cells (Figure 4a ). Cotransfection with the wild-type human PPARg1 did not further enhance luciferase activity compared to ligand-induced mock-transfected cells (not shown). This may be attributed to high levels of endogenously active PPARg in this cell line. In contrast, in cells transfected with the dominant-negative DN-PPARgD459 construct, luciferase activity was profoundly suppressed in both control and rosiglitazone-treated cells ( Figure 4a ). Quantitative analysis of caveolin-1 and -2 bands from four independent experiments revealed that in mock-transfected cells rosiglitazone increased expression of caveolin-1 and -2 by 2.270.3 and 2.870.2-fold compared to vehicletreated cells (Figure 4b ,c). Again, transfection of the wild-type human PPARg1 construct did not further increase caveolin levels (not shown). The dominantnegative DN-PPARgD459 construct had little or no effect on basal caveolin levels. However, DNPPARgD459 attenuated ligand-induced expression of caveolin-1 by 84% and of caveolin-2 by 65%, compared to ligand-induced caveolin levels in mock-transfected cells (Figure 4b ), while the expression levels of actin were unaffected (Figure 4c ). These data clearly indicate that stimulation of caveolin expression by rosiglitazone is mediated by activation of PPARg. We have further studied the effect of dominantnegative PPARg at the level of single cells using immunofluorescence microscopy ( Figure 5 ). HEK-293 T cells were grown on coverslips at low density (o30%), transfected with a GFP-control vector and either wild-type PPARg or DN-PPARgD459 constructs, and then stimulated with rosiglitazone (10 mm) for 48 h. Upon fixation and permeabilization, the cells were immunostained against caveolin-1 using a rhodamineconjugated secondary antibody and nuclei were visualized using DAPI. Transfected cells were visualized by GFP autofluorescence. Rosiglitazone strongly increased the fluorescence intensity for caveolin-1 compared to vehicle-treated mock-transfected cells ( Figure 5 ). Transfection of the wild-type PPARg slightly enhanced caveolin-1 fluorescence intensity in the rosiglitazonetreated cells. In contrast, ligand-induced caveolin-1 fluorescence was clearly abrogated in cells transfected with the dominant-negative DN-PPARgD459 construct, supporting a function of PPARg in rosiglitazoneactivated upregulation of caveolin-1 in these cells. therefore performed immunofluorescence microscopy in order to determine if upregulation of caveolins is coordinated with changes in cell-specific differentiation markers. HT-29 cells were grown to confluency on coverslips and differentiated in vitro for additional 4 days with rosiglitazone (at 10 mm). Cells were fixed and stained for villin, a differentiation marker for intestinal enterocytes (Figure 6a ). This treatment did not lead to an increase in the staining intensity, although an increased complexity of the villin intermediary filaments was apparent. We then treated subconfluent HT-29 cells for 5 days with rosiglitazone (at 10 mm). The total expression levels of villin (94 kDa) remained largely unaffected by rosiglitazone although it increased gradually during culture in both control and ligand-treated cells (Figure 6b,c) . In contrast, confluency and differentiation caused a decrease in caveolin expression which was prevented by rosiglitazone (compare blots in Figures 2a and 6c , which are from the same samples blotted with caveolin-1 and villin antibodies, respectively). In summary, these observations indicate that in HT-29 cells, early induction of caveolin expression by PPARg ligands (Figures 2 and 3) is independent of and clearly precedes changes in enterocyte differentiation markers.
Lipid droplets are characteristic markers for adipocytes (Brown, 2001) which are induced upon differentiation of breast cancer cells with PPARg ligands (Mueller et al., 1998) . Thus, MCF-7 cells were grown to confluency and induced to differentiate with 5 mm PhAc for additional 4 days at postconfluency, fixed and stained with Nile red (Figure 7a ). MCF-7 cells treated with PhAc (5 mm) developed within days cytoplasmic lipid droplets that accumulated around the nuclei of the PhAc-differentiated cells, eventually forming a perinuclear corona after 4 days at postconfluency. In addition, the expression of the breast epithelial marker maspin was determined in MCF-7 cells, as this marker is induced by PPARg-ligand-mediated differentiation (Mueller et al., 1998) . Incubation of subconfluent MCF-7 cells for 5 days with PhAc (at 5 mm) resulted in a substantial increase in maspin expression (Figure 7b ). For better comparison with the pattern of caveolin-2 induction, a representative blot showing the samples from Figure 2b , which were rerun and reblotted with maspin antibodies, is shown in Figure 7c . We conclude that in MCF-7 cells caveolin-2 induction is coordinated in a similar time course with PPARginduced differentiation. In summary, these data indicate that early upregulation of caveolins by PPARg ligands is an acute effect that precedes or is concomitant to induction of differentiation markers and may contribute to the subsequent differentiation program of these tumor cells in a tissue-specific manner.
Targeting of caveolin-1 and -2 to lipid rafts upon treatment with PPARg ligands
Caveolin-1 is localized in plasma membrane caveolae in many but not all cells (Li et al., 2001b) . It was therefore of interest to determine whether, in adenocarcinoma cells, PPARg-induced caveolins localize to caveolar membranes. The specific sphingolipid-and cholesterolenriched composition of lipid rafts and caveolae facilitates their purification by sucrose density gradient centrifugation . Triton X-100-insoluble membranes were prepared from lysates of HT-29 cells, fractionated in a discontinuous sucrose density gradient and analysed for caveolin-1 and -2 by Western blot. Lipid rafts/caveolae-associated proteins are concentrated in low-density fractions 5 and 6 . Upon treatment of HT-29 cells with 10 mm ciglitizone for 3 days, the levels of caveolin-1 targeted to the lipid rafts-containing fractions were increased, while there was little effect on caveolin in other fractions (Figure 8a ). Similar results were obtained with caveolin-2 (not shown). MCF-7 cells that were treated for 24 h with 1 mm PhAc similarly exhibited enhanced expression of caveolin-2 localized in lipid rafts-containing fractions and, to a lesser extent, also of caveolin-1 (not shown). The latter was not observed in unfractionated cell lysates (cf. Table 1 ), but observed only after enrichment by sucrose gradient. These data suggest that caveolin-1 is upregulated by PPARg also in MCF-7 cells, as expected based on the mRNA data (cf. Figure 3c ,e), albeit to a much lesser extent than in HT-29 cells. We conclude that in both adenocarcinoma cell types examined here, PPARg-induced caveolins are targeted to caveolar membranes and thus may be involved in typical caveolae-dependent functions.
Association of PPARg with caveolins in lipid rafts
In ligand-treated HT-29 cells (3 days, 10 mm troglitazone), PPARg itself partially (B15%) cofractionated with caveolin-1 in fractions 5 and 6, although the bulk of PPARg was found in detergent-soluble fractions (9-11) and in the pellet (fraction 12) (Figure 8b ). Vehicletreated control cells exhibited a similar percentage of lipid raft-associated PPARg and similar results were obtained in MCF-7 cells (not shown). We next performed coimmunoprecipitation experiments in order to examine if there is an association between PPARg and caveolin-1. Owing to their high content of endogenous caveolin proteins (Lavie et al., 1998) , we used HT-29-MDR cells for this purpose. Cells were lysed in RIPA buffer in room temperature (conditions known to disrupt rafts integrity) and proteins were immunoprecipitated with polyclonal antisera against caveolin-1 and PPARg. Western blot analysis revealed that the PPARg antiserum was able to pull down substantial amounts of caveolin-1 from the cell lysate, whereas the control beads did not (Figure 8c , left panel).
In the reciprocal experiment, caveolin-1 antiserum, but not the beads alone, precipitated PPARg from the cell lysate ( Figure 8c , right panel). These results indicate that PPARg is partially colocalized with caveolin in raftenriched membranes, where it is likely to exist in a complex with caveolin-1.
Discussion
In the present study, we show, for the first time, that caveolin-1 and -2 are target genes for PPARg in human cancer cells. Caveolin protein and mRNA expression are induced by the highly specific glitazone family PPARg ligands as well as by the putative physiological agonists 15dPGJ 2 and PhAc. The effects of the PPARg ligands is dose-and time-dependent. The upregulation of caveolins is an early event that precedes PPARg-induced differentiation and is significantly inhibited by a dominant-negative PPARg construct. PPARg ligands diffuse across the plasma membrane and in the cytosol they bind to the ligand-binding domain of PPARg, inducing a conformational change in the AF-2 domain, which leads to dimerization with RXR, the release of corepressors and recruitment of coactivators (Nolte et al., 1998; Murphy and Holder, 2000) . These events eventually lead to interaction of the DNA-binding domains of the heterodimer with appropriate promoter regions. We could not identify in the proximal and distal promoter regions of the CAV1/ CAV2-genomic locus a bona fide PPRE, defined by a direct repeat-1 (DR-1) consensus binding element (i.e. AGGTCA(N3)AGGTCA) for the PPARg/RXR heterodimer. However, PPARg does not necessarily depend on a cognate binding site in the DNA in order to transactivate a target gene promoter. PPARs are known to establish multiple protein-protein interactions with a variety of other transcription factors (e.g. Ets-1, NF-kB, AP-1, STAT) and cofactors (p300/CBP) and modulate their activity (Nolte et al., 1998; Murphy and Holder, 2000; Fajas et al., 2001 ). Nevertheless, further molecular studies with caveolin promoter constructs are necessary to establish its exact mode of activation.
In cancer cells, the caveolin-1 protein levels are actively downregulated by epigenetic modification (e.g. methylation of the promoter) and by repressive transcription factors (Engelman et al., 1999a; Fra et al., 2000) , whereas the negative control of caveolin-2 transcription seems to be far more relaxed (Engelman et al., , 1999b Galbiati et al., 1998a; Racine et al., 1999; Yamamoto et al., 1999) . Indeed, we found a differential and cell-specific response to selected PPARg ligands in breast and colon adenocarcinoma cells concerning the regulation of caveolin-1 vs -2 expression. In both cell lines, caveolin-2 was upregulated substantially by PPARg ligands. Interestingly, the cell types differed in their sensitivity to different classes of ligands. HT-29 cells responded mainly to the glitazones, whereas MCF-7 cells responded better to the nonglitazone ligands PhAc and 15dPGJ 2 . Indeed, it was recently discovered that various ligands display a variable, ligand-selective requirement for distinct structural determinants in PPARg that are coactivator-specific, possibly explaining the cell type-specific actions of different ligands (Wu et al., 2003) . Caveolin-1 protein was strongly upregulated by the glitazones in HT-29 cells, whereas in MCF-7 cells its induction was much lower and was observable only upon fractionation of raft-enriched membranes. This difference may be explained by the wild-type p53 status of MCF-7 cells (Gobert et al., 1999) . p53 is a strong suppressor of caveolin-1 transcription (Bist et al., 2000; Razani et al., 2000) . In contrast, HT-29 cells have a mutant p53 (Gobert et al., 1999) , a fact that may relax the tight control of the caveolin-1 gene. Another explanation may relate to the fact that the proximal caveolin-1 promoter region in MCF-7 cells may contain methylated CpGrich islands that silence its transcription (Engelman et al., 1999a) . This methylation was not found in other tumorderived cell lines (Hurlstone et al., 1999) , pointing at a cell-specific silencing mechanism in MCF-7 cells. In addition, each cell line has its own repertoire of nuclear receptor coactivators and/or corepressors which may differentially crosstalk with one another (Qi et al., 2000; Fajas et al., 2001) . Also, in sharp contrast to steroid hormone receptors, the ligand-binding pocket of PPARg is relatively promiscuous and recognizes a range of structurally diverse agonists (Nolte et al., 1998; Fajas et al., 2001) . Hence, crosstalk with endogenous ligands and different metabolism and turnover rates for each exogenous ligand could modulate the activity of exogenously applied agonists. The combination of all these factors may explain the cell-specific and differential effects of the selected ligands on caveolin expression, as observed in our study.
Our data suggest that PPARg-regulated caveolin expression is not necessarily correlated with the differentiation program of carcinoma cells. In support of this conclusion, in cells that were seeded at low density and did not reach confluency before exposure to the ligands, induction of caveolin-1 mRNA and protein was an acute event which was observable within 3-24 h and preceded the onset of differentiation. Nevertheless, upon prolonged exposure of confluent cells to PPARg ligands (3-9 days), a sustained ligand-dependent elevation of caveolin levels was evident, whereas in control cells caveolin levels decreased over time. This was accompanied by enhanced expression of the differentiation marker maspin in breast carcinoma cells but not of villin in colon epithelial carcinoma cells. Accordingly, basal expression levels (primarily of caveolin-2) were found to be increased during repeated passage and postconfluency of MCF-7 cells (E Burgermeister, unpublished data), a phenomenon likely linked to spontaneous differentiation and increased cell-cell contacts (Galbiati et al., 1998a; Volonte' et al., 1999) .
Taken together, the data showing that caveolins are upregulated by PPARg ligands are consistent with the proposed function of caveolin-1 as a growth-inhibitory and differentiation-promoting protein in a cell typedependent manner. The restoration of caveolin expression by PPARg ligands in cancer cells is likely to play a major role in suppressing their tumorigenic phenotype. It has been demonstrated that forced re-expression of caveolin-1 in transformed cells leads to reduced proliferation rates, loss of anchorage-independent growth, inhibition of matrix metalloprotease release and invasiveness and blockage of MAP-kinase signaling Lee et al., 1998; Fiucci et al., 2002) .
However, the role of caveolin-1 has been complemented recently by reports about its apparent survivalpromoting actions. Secreted caveolin-1 supports growth, survival and metastasis of prostate cancer cells (Tahir et al., 2001 ) and expression of caveolin-1 inhibits anoikis in MCF-7 cells (Fiucci et al., 2002) . Additionally, testosterone-induced caveolin-1 promotes growth and metastasis of prostate cancer cells in vitro and in vivo (Li et al., 2001a) . These tumor-promoting actions of caveolin-1 may be related to its interaction with steroid hormone receptors. Androgen and estrogen receptors physically associate with caveolae but are released and translocated to the nucleus in a ligand-dependent manner (Schlegel et al., 1999; Lu et al., 2001) . In the nucleus, these receptors modulate transcription of the caveolin-1 gene itself, thus establishing an autoregulatory feedback loop (Razandi et al., 2002) . Our data showing the partial cofractionation of PPARg in caveolin-rich lipid rafts and residence of caveolin-1 in a complex with PPARg may indicate a similar situation for this transcription factor. Facing an increasing panel of caveolin-interacting proteins, resolving the observations of discrepant anti-or pro-tumor functions of caveolin in different cellular systems must await the elucidation of the underlying molecular mechanisms.
In this context, it is interesting to note that acquisition of MDR by human cancer cell lines is often accompanied by elevated expression of caveolin-1 and by increased density of cell surface caveolae (Lavie et al., 1998; Yang et al., 1998; Bender et al., 2000) . Preliminary results from our laboratory indicate that PPARg ligands superinduce caveolin-1 expression in human MDR cancer cell lines (E Burgermeister et al., manuscript in preparation) . Thus, PPARg may be involved in regulation of caveolin expression in both drug-sensitive and drug-resistant cancer cells. If high expression of caveolin-1 is causally related to the MDR phenotype (e.g. by promoting cell survival), the present data raise the possibility that by upregulating caveolin levels in cancer cells, PPARg may be a 'risk factor' for MDR. Obviously, much work is required in order to critically examine these intriguing hypotheses.
The present findings may have important implications for the use of PPARg ligands in tumor differentiation therapy. Differentiation therapy is a recent, promising approach in oncology that is currently undergoing clinical trials (Mueller et al., 2000) . This approach is based on the ability of PPARg ligands to initiate a differentiation program in human cancer cells (Tontonoz et al., 1997; Elstner et al., 1998; Kubota et al., 1998; Demetri et al., 1999; Kitamura et al., 1999) by modulating transcription of numerous genes coding for proteins (e.g. p21 (WAF1/Cipl) , Bcl-2, E-cadherin) which drive tumor cells into terminal differentiation and growth arrest or apoptosis, depending on the tissue origin of the tumor. Our data indicate that caveolin-1 is a transcriptional target of PPARg and suggest that it may be an important mediator of the phenotypic changes induced by this clinically important nuclear receptor in cancer cells.
Materials and methods
Reagents
All chemicals and materials were from Merck and Sigma unless stated otherwise. 15dPGJ 2 was from Calbiochem. Troglitazone and rosiglitazone were gifts from Roche Diagnostics (Mannheim). The expression plasmid pSG5-hPPARg1 and the reporter plasmid 3 Â PPRE-TK-luc were kindly provided by Dr Markus Meyer (Hoffmann La Roche, Basel). The dominant-negative construct pCMX-DN-hPPARgD459 was a generous gift from Dr Yaakov Barak (Salk Institute, La Jolla, CA, USA). Mouse monoclonal antibodies against caveolin-2 and villin were purchased from Transduction Laboratories. The mouse monoclonal antibody against maspin was from Pharmingen. The goat polyclonal actin antiserum and the rabbit polyclonal caveolin-1 antiserum were from Santa Cruz Biotechnology. Secondary antibody conjugates were from Jackson Immunoresearch. Protein analysis was performed using the BCA Protein Assay Reagent (Pierce).
Cell culture
Human breast adenocarcinoma MCF-7 cells were grown as monolayer cultures at 371C in a humidified atmosphere containing 5% CO 2 in RPMI-1640 medium supplemented with 10% (v/v) heat-inactivated fetal calf serum (FCS), penicillin and streptomycin (1000 U/ml each) and glutamine (20 mm) (all from Biological Industries). Human colon adenocarcinoma HT-29 and human embryonic kidney HEK-293T cells were grown in Dulbecco's modified Eagle medium (Gibco BRL Life Technologies) with penicillin/streptomycin (1000 U/ml each), 20 mm glutamine and 10% (v/v) FCS. The multidrug resistant human colon adenocarcinoma cell line HT-29-MDR was grown like the parental cell line but in the continuous presence of 300 ng/ml colchicine. Increased basal expression of caveolin-2 was observed during prolonged passage of the cells (data not shown). Therefore, only low passage numbers (5-15) were used for the experiments.
In vitro differentiation assay
Cells were grown to confluency in 100-mm dishes or on coverslips in six-well plates, for biochemical and immunofluorescence analyses, respectively. At 1 day after confluency, the ligand was added for additional 3-7 days. Every day the medium was replaced and fresh ligand added. Differentiation was monitored by increased expression of differentiation markers as determined by Western blot analysis and immunofluorescence microscopy (see below).
Transient transfection and reporter assay
Cells were grown to 50% confluency in 100-mm dishes or on cover slips when used for immunofluorescence microscopy (see below). The cells were then transiently cotransfected with 5 mg/ dish of the 3 Â PPRE-TK-luc reporter plasmid and 10 mg/dish of the PPARg expression plasmids using LipofectAMINE (Gibco BRL Life Technologies) according to the manufacturer's instructions. Equal transfection efficiency (B60%) was monitored by cotransfection of 2 mg/dish pEGFPC1 (Clontech), a green fluorescent protein control vector. After 24 h, the transfection mixture was replaced by complete medium containing freshly diluted PPARg ligand or vehicle (DMSO) and the cells were incubated for an additional 48 h. At 72 h after transfection, cells were lysed and Western blots were performed as described below. Luciferase activity in cell lysates was measured with a kit (Promega) according to the manufacturer's instructions using a luminometer (Lumac s 13M, Biocounter) and normalized against the total protein content in the samples.
Immunofluorescence microscopy
Cells were fixed on coverslips for 30 min in 3% (w/v) paraformaldehyde in phosphate-buffered saline (PBS), followed by a 5 min permeabilization in 0.2% (v/v) Triton X-100 in PBS at room temperature. Caveolin-1 and villin were detected by incubation of the coverslip in a 1 : 50 dilution of the primary antibodies for 1 h at room temperature. After extensive washing, coverslips were further incubated in 1 : 250 dilutions of either anti-mouse-IgG-Rhodamine X red conjugates for 1 h. Lipid droplets were visualized upon a 15 min incubation with 100 nm Nile Red in PBS, nuclei with 0.1 mg/ml 4 0 ,6-diamidino-2-phenylindole (DAPI) in PBS. Slides were photographed using a digital camera-connected fluorescence microscope (Zeiss) with Â 200 and Â 400 magnifications. Comparability of fluorescence intensity was guaranteed by using equal image acquisition parameters for all slides within the same experiment.
Cell lysis and Western blotting
For detection of total solubilized caveolin-1 and -2, cells were extracted with lysis buffer S (2% (w/v) SDS, 50 mm Tris-HCl, pH 7.6) and protease inhibitors at room temperature. The lysate was sonicated and debris was removed by centrifugation at 14 000 r.p.m. for 10 min at 41C. Aliquots of supernatants were boiled in SDS-loading buffer (12.5 mm Tris base, pH 11.25; 2% (w/v) SDS, 1% (v/v) b-mercaptoethanol, 10% (v/v) glycerol, 0.00125% (w/v) bromophenol blue), respectively. Proteins were separated by SDS-PAGE together with a prestained molecular weight marker (Low Range, Biorad) and detected by Western blot analysis. Briefly, proteins were transferred to nitrocellulose membranes and blocked with either 2% (w/v) bovine serum albumin (BSA) (if actin antiserum was to be used) or 10% (w/v) skim milk in PBS containing 0.1% (v/v) Triton X-100 (T-PBS). Immunoblot analyses were performed with 1 : 1000 dilutions of the primary antibodies either in T-PBS containing 2% (w/v) BSA (in case of actin antiserum) or T-PBS alone. Blots were washed extensively and incubated with horseradish peroxidase-linked goat anti-mouse/rabbit IgG or rabbit anti-goat IgG, diluted 1 : 15 000 in either T-PBS with 2% (w/v) BSA (if actin antiserum was used) or in T-PBS containing 5% (w/v) skim milk. Bands were visualized by enhanced chemiluminescence (ECL, Amersham).
Isolation of low-density Triton X-100-insoluble caveolin-rich lipid rafts
For isolation of the lipid-raft associated caveolin-1 and -2, low density Triton X-100-insoluble membrane domains were purified from cells as described . Two 150-mm dishes with confluent monolayers were scraped on ice in 1 ml of ice-cold lysis buffer M. After Dounce homogenization (20 strokes), extracts were adjusted to 40% (w/v) sucrose and loaded on the bottom of a discontinuous 30% (w/v) to 5% (w/v) sucrose gradient. The tubes were then ultracentrifuged in a SW-41 rotor at 19 0000 g for 20 h at 41C. Eleven fractions (900 ml each) were collected from the top of the tube and the pellet was resuspended in 0.9 ml of buffer M and designated fraction 12. Aliquots taken from each of the fractions were subjected to SDS-PAGE and Western blot analysis.
Immunoprecipitation
Cells (two confluent 150-mm dishes) were subjected to lysis in 1 ml of immunoprecipitation (RIPA) buffer (50 mm Tris, pH 7.5, 150 mm NaCl, 1% (v/v) Nonidet P-40, 0.5% (w/v) deoxycholate, 0.1% (w/v) SDS and 0.1 mm Na 3 VO 4 , 1 mm phenylmethylsulfonyl fluoride, 10 mg/ml aprotinin and 10 mg/ ml leupeptin). Lysis was performed at room temperature in order to completely solubilize membrane-bound caveolins. Cellular debris was removed by centrifugation at 12 000 g for 10 min at 41C. PPARg and caveolin-1 antisera (2 mg) were incubated at 41C and under constant shaking with 30 ml of a slurry of protein A/G-agarose (Santa Cruz) for 24 h. The lysates (400 mg of total protein) were then incubated at 41C with a 1 : 1 slurry of either protein A/G-agarose alone (bead control) or antibody-coupled protein A/G-agarose for 2 h in RIPA buffer. Immune complexes were collected by centrifugation, washed three times with RIPA buffer, solubilized by boiling in 30 ml SDS-loading buffer and subjected to SDS-PAGE and Western blot analysis.
RT-PCR
Total RNA was extracted using TriPure Isolation Reagent (Roche Diagnostics) according to the manufacturer's instructions. Reverse transcription and PCR was performed using the Access RT-PCR System (Promega) according to the manufacturer's instructions. Semiquantitative estimation of caveolin-1 mRNA levels was achieved by setting up RT-PCR reactions with serial 10-fold dilutions of 1 mg of total RNA. PCR amplification was stopped after 20, 25, 30 or 40 cycles (T m ¼ 531C) and the amplification products were analysed by ethidium bromide agarose gel electrophoresis using the DNA molecular weight marker SmartLadder (Eurogentec). Results obtained from the primer pair directed against the cDNA of human caveolin-1 Cav-1(F) 5 0 -ATGTCTGGGGGCAAATA-CGTAGACTCGGAG-3 0 and Cav-1(R) 5 0 -TTATATTTCTT-TCTGCAAGTTGATGCGGAC-3 0 were normalized to the fragment derived from the primer pair S16(F) 5 0 -CGTTCA-CCTTGATGAGCCCATT-3 0 and S16(R) 5 0 -TCCAAGGGT-CCGCTGCAGTC-3 0 directed against the cDNA of human ribosomal protein S16.
Quantitation and statistical evaluation
Quantitative analysis of bands on X-ray films was performed using the software Quantity One s (Bio-Rad). Statistical significance was calculated using Student's t-test.
Abbreviations 15dPGJ 2 , 15-desoxy-D 12,14 -prostaglandin J 2 ; MDR, multidrug resistance; PhAc, phenyl acetate; PPARg, peroxisome proliferator-activated receptor-g; PPRE, PPAR-responsive element; RXR, retinoid X receptor
